Executive Summary of the ARS Appropriate Use Criteria for Local Excision in Rectal Cancer

The goal of treatment for early stage rectal cancer is to optimize oncologic outcome while minimizing impact of treatment on quality of life. The standard of care treatment for most early rectal cancers is radical surgery alone. Given the morbidity associated with radical surgery, local excision for early rectal cancers has been explored as an alternative approach associated with lower rates of morbidity. The American Radium Society Appropriate Use Criteria (ARS AUC) presented in this manuscript are evidence-based guidelines for the use of local excision in early stage rectal cancer that includes an extensive analysis of current medical literature from peer-reviewed journals and the application of a well-established consensus methodology (modified Delphi) to rate the appropriateness of imaging and treatment procedures by a multidisciplinary expert panel.
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Tags: Critical Review Source Type: research

Related Links:

ConclusionCapOX therapy is feasible as adjuvant chemotherapy for locally advanced rectal cancer.
Source: International Journal of Clinical Oncology - Category: Cancer & Oncology Source Type: research
Conclusions: Transanal total mesorectal excision offers a safe and feasible alternative to LaTME although the clinicopathological features were not superior to LaTME in this study. Currently, with the lack of evidence on benefits of TaTME, further evaluation of TaTME requires large randomized control trials to be conducted. PMID: 31534564 [PubMed]
Source: Videosurgery and Other Miniinvasive Techniques - Category: Surgery Tags: Wideochir Inne Tech Maloinwazyjne Source Type: research
Journal of Laparoendoscopic&Advanced Surgical Techniques, Ahead of Print.
Source: Journal of Laparoendoscopic and Advanced Surgical Techniques - Category: Surgery Authors: Source Type: research
Conditions:   Rectal Neoplasms;   Rectal Cancer Intervention:   Radiation: Preoperative Radio(Chemo)Therapy Sponsors:   Maria Sklodowska-Curie Institute - Oncology Center;   Polish Society of Surgical Oncology Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Rectal Cancer Intervention:   Sponsor:   Mahidol University Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Cancer of Rectum Interventions:   Radiation: 50.4 Gy to the tumor and elective volume;   Radiation: 62 Gy to the clinical tumor volume and 50.4 Gy to the elective volume;   Drug: Capecitabine 825 mg/m2 twice daily on weekdays Sponsor:   Vejle Hospital Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Rectal Neoplasms;   Rectal Cancer Intervention:   Radiation: Preoperative Radio(Chemo)Therapy Sponsors:   Maria Sklodowska-Curie Institute - Oncology Center;   Polish Society of Surgical Oncology Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Rectal Cancer Intervention:   Sponsor:   Mahidol University Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Cancer of Rectum Interventions:   Radiation: 50.4 Gy to the tumor and elective volume;   Radiation: 62 Gy to the clinical tumor volume and 50.4 Gy to the elective volume;   Drug: Capecitabine 825 mg/m2 twice daily on weekdays Sponsor:   Vejle Hospital Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Rectal Cancer Intervention:   Sponsor:   Mahidol University Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Biology | Cancer | Cancer & Oncology | Physics | Radiology | Rectal Cancers